This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.
NeoMedigen Limited Announces Name Change
Hamilton, Bermuda - 24 September, 2013 – NeoMedigen Limited (the "Company"; Ticker: NEOM.BH), a public company listed on the Bermuda Stock Exchange ("BSX"), announced today that the Company name has changed to RezGen 5, Limited.
The Company held a Special General meeting of the Shareholders on Friday, 30 August, 2013, wherein the shareholders voted in favor of the name change.
NeoMedigen founder and CEO Stuart Garrett commented, “We feel that rebranding the Company will serve to better identify our Company to consumers as our products come to market.”
Existing shareholders of Neomedigen should be aware that the name change has resulted in a change in the Company’s International Securities Identification Number ("ISIN") and Ticker Symbol.
RezGen 5, Limited
RezGen 5, Limited is a Bermuda based biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with ageing, including metabolic diseases such as Type 2 Diabetes, Alzheimer’s and cardiovascular diseases. RezGen 5, Limited is committed to improving the quality of human life by enabling people to do more, feel better and live longer. The company's headquarters are in Hamilton, Bermuda. For company information including a copy of this announcement and details of the company’s updated product development pipeline, visit www.rezgen5.com
Cautionary statement regarding forward-looking statements
The company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk factors' in the 'Business Review' in the company's website.
This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Rezgen5 Limited Investors and security holders are urged to read each of these documents carefully when they are available. In addition, investors and security holders will be able to obtain free copies of these documents by contacting the Investor Relations departments of RezGen5 Limited.
Contact: info@rezgen5.com
Bermuda Listing Sponsor:
Butterfield Securities Ltd.
Attn: Wendy Tucker-Adams, TEP| AVP, Corporate Trust Department
Butterfield Trust (Bermuda) Limited
Hamilton, Bermuda
Tel: 441 298 4801
Fax: 441 292 1258